Monday, 24 May 2021

Medical Image Management Market Report 2020 with Key Players, Regions, Trends, Market Growth, SWOT Analysis and Forecast to 2027

 Global Medical Image Management Market analysis by MRFR expected to register a CAGR of 7.80% to reach USD 5,971.28 Million till 2025. Medical image management systems are used in hospitals and diagnostic centers for sharing patient data and laboratory results with physicians. These systems are very useful and help in maintaining patient data, which plays an important role in clinical decision making.

The rising prevalence of chronic diseases, increasing spending on the healthcare it sector, and technological advancements in diagnostics sector are expected to enhance the market growth. However, the high costs of software solutions and privacy and security concerns are projected to curb the growth of the market.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/8312

Market Dynamics

The market is expected to witness a profitable growth owing to the rising prevalence of chronic diseases. According to the data by the Government of Canada, in 2017, about 2.3 million people aged 12 and older were diagnosed with diabetes. Additionally, according to the press release by Chiron Health published in June 2016, chronic diseases such as heart disease, stroke, cancer, depression, type 2 diabetes, obesity, and arthritis affected an estimated 117 million people in the Americas. The medical image management technology could be used to address the issues related to the data collection and sharing of laboratory results and rising demand for healthcare services related to the diagnosis of cancer, diabetes, and other diseases in the North American region.

Thus, the rising prevalence of chronic diseases is expected to drive the growth of the global medical image management market.

Segmentation

The global medical image management market, by product, has been segmented into picture archiving and communication system, vendor-neutral archive (VNA), application-independent clinical archives, and enterprise viewers/universal viewers.Based on end user, the medical image management market has been categorized as hospitals, diagnostic imaging centers, and others.

Regional Analysis

The global medical image management market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

The Americas accounted for the largest market in 2018 and is estimated to dominate the global medical image management market owing to the increasing prevalence of chronic diseases, rising adoption of healthcare IT by healthcare bodies, and an increasing number of medical imaging procedures performed.

Europe acquired the second largest market share in 2018. It is expected to register a CAGR of 8.12% by the end of the forecast period. The European market is expected to register a sturdy growth rate during the forecast period due to major driving factors such as the rising patient population of strokes and cardiovascular disorders, increasing research on ultrasound, and availability of advanced treatment facilities amongst others. For instance, according to the 2017 statistics presented by the European Society of Cardiology, there were more than 6 million new cases of cardiovascular diseases in the European Union and more than 11 million in Europe as a whole.

Asia-Pacific is expected to witness significant growth and is projected to be the fastest-growing region over the forecast period. The high growth rate is due to the rising demand for medical practitioners to produce appropriate vascular, orthopedic, breast, and cardiac images and integration of reports, images, and measurements into a patient’s complete record. India held a share of 17.8% in the Asia-Pacific medical image management market in 2018.

The Middle East & Africa accounted for the least market in 2018 and is forecasted to exhibit steady growth due to the high price of devices, lack of awareness regarding health, and lack of skilled professionals.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/medical-image-management-market-8312

About US:

 

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Posted by at No comments:

Alpha-1 Antitrypsin Deficiency Treatment Market Size, Share, Demand, Financial Overview, Key Developments, Swot Analysis and Forecast to 2027

 Market Forecast

Global Alpha-1 Antitrypsin Deficiency Treatment Market is expected to cross USD 2,914.7 Million by 2025 at a CAGR of 10.50%.

Growing product pipeline for alpha-1 antitrypsin drugs and rising prevalence of alpha-1 antitrypsin deficiency are set to drive the market growth for alpha-1 antitrypsin deficiency treatment. Approximately 100,000 people in the US are known to suffer from alpha-1 antitrypsin deficiency.

Rising awareness regarding the alpha-1 antitrypsin deficiency is expected to drive the growth of the global alpha-1 antitrypsin deficiency treatment market.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/8319

The market is dominated by numerous established players. The key players are involved in product launches, strategic collaborations, and awareness programs to strengthen their market positions. For instance, in November 2018, Grifols S. A. launched the AlfaCare therapy program for training and counseling of patients diagnosed with alpha-1 antitrypsin deficiency.

Market Influencer

The prevalence of alpha-1 antitrypsin deficiency (AATD) is increasing, which is directly responsible for the growth of the global alpha-1 antitrypsin deficiency treatment market. Strategic initiatives, mergers & acquisitions, partnerships, agreements, product launches, government approvals, and expansion of manufacturing facilities by major competitors are expected to further boost market growth during the forecast period.

Segmentation

By Drugs:

  • Alpha-1 Proteinase Inhibitor: The segment is expected to hold the largest Alpha-1 Antitrypsin Deficiency Treatment Market share as it is the only treatment for AATD, which protects the patient from more lung damage.
  • Bronchodilators: These are used for the treatment of respiratory disorders associated with AATD.
  • Steroids: These are used specifically for the treatment of chronic obstructive pulmonary disease, which affects the patient along with AATD.
  • Others: Other treatment options include antibiotics for infections and jaundice associated with AATD and oxygen therapy.

By Route of Administration:

  • Oral: The segment is expected to hold the largest market share.
  • Intravenous: The segment is expected to grow at the fastest CAGR.
  • Inhalation: This route of administration is used specifically for the administration of corticosteroids for treating breathing disorders.
  • Others: Subcutaneous and intramuscular routes of administration.

By Distribution Channel:

  • Hospital Pharmacy: The rise in the number of hospitals is likely to be responsible for the largest market size.
  • Retail Pharmacy: These fulfill the requirement of drugs that are needed for treatment at home.
  • Online Stores: The fastest-growing segment owing to increase in number of online pharmacies.

By Region

  • Americas: The region holds the largest share of the market. The market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada.
  • Europe: The European alpha-1 antitrypsin deficiency treatment market has been classified as Western Europe and Eastern Europe. The Western European market has further been categorized as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
  • Asia-Pacific: The market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The Asia-Pacific alpha-1 antitrypsin deficiency treatment market is projected to be the fastest-growing during the forecast period.
  • Middle East & Africa: The market in the Middle East & Africa has been divided into the Middle East and Africa.

  • Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/alpha-1-antitrypsin-deficiency-treatment-market-8319

    About US:

     

    Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

    Contact Us:

    Market Research Future

    Office No. 528, Amanora Chambers

    Magarpatta Road, Hadapsar,

    Pune – 411028

    Maharashtra, India

    Phone: +1 646 845 9312

    Email: sales@marketresearchfuture.com

Posted by at No comments:

Cell Lysis and Disruption Market Foraying into Emerging Economies 2020-2027

 Global Cell Lysis & Disruption Market is expected to cross USD 5.7 Billion by 2025 at a CAGR of 8.6%.

Market Synopsis

Cell lysis & disruption is a method in which the cell membrane is broken down in order to extract the nucleic acids or proteins from a cell. The choice of cell lysis method depends on the type of cells, concentration, application (post-processing) and efficiency required. The demand for cell lysis & disruption is increasing due to the rising number of research & development activities in the biotechnology industry. This is majorly attributed to the increasing adoption of biotech processes in the pharmaceutical, agricultural sector.

Market Influencer

The expansion of the biopharmaceutical sector and growing advancements in personalized medicine is positively influencing the market. Moreover, the rising demand for novel therapeutics and the increasing prevalence of diseases is responsible for positive market growth.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/8358 

Market Drivers

  • Expanding biotechnology and biopharmaceutical industries. For example, the biotechnology industry in India is growing at a high pace. It comprises about 800 companies, is expected to be valued at USD 11.6 billion in 2017. Moreover, the government of India has invested USD 5 billion to initiate research in the field of biotechnology.
  • The increasing prevalence of chronic diseases, including cancer. The incorporation of genetic and molecular techniques in personalized medicine via human genome research helps to determine best treatment options which are expected to drive the growth of cell lysis & disruption market share.
  • Increasing government funding for research
  • Rising focus on personalized medicine
  • Technological advancements in cell disruption techniques

Market Restraints

  • Shortage of skilled personnel
  • The high maintenance cost of equipment

Segmentation

By Technique

  • Reagent Based: The largest segment, higher biological specificity of enzymatic disruption is attributive to the growth of this segment size. The reagent based segment is further segmented into detergent and enzymatic.
  • Physical Disruption: Physical or mechanical methods of cell disruption have traditionally been the method of choice for cell lysis. Physical disruption method includes mechanical homogenization, ultrasonic homogenization, pressure homogenization, and temperature treatments.

By Product

  • Consumables: The fastest-growing segment owing to the increasing prevalence of diseases and rise in funding of cell-based research is a crucial factor for the growth of the segment. Consumables are further divided into reagent and kits, beads, and disposables.
  • Instruments: The commercial availability and reliability of tools that are used in cell disruption & lysis are boosting the growth of this segment. The instrument segment is further categorized as sonicators, homogenizers, French press, microfluidizer, and others.

By Cell Type

  • Mammalian Cells: The largest segment, this is attributable to Increased investments in R&D linked to biotechnology by government organizations and the private sector. Furthermore, the primary vital players have developed reagents that specifically work on mammalian cells, which is attributing to the growth of this segment. For instance, Merck offers a wide range of mammalian cell lysis reagents which are used for the preparation of mammalian phosphorylated, cytosolic, and nuclear proteins.
  • Microbial Cells: The expansion of the biopharmaceutical sector and increasing research is responsible for positive growth.
  • Others: This segment covers plant cells.

By End-User

  • Research Laboratories and Institutes: The largest segment, increased use of cell disruption techniques in research facilities is projected to drive the growth of this segment during the forecast period.
  • Pharmaceutical and Biotechnology Companies: A small segment due to the rising occurrence of diseases and growing research & development is projected to boost the growth of this segment.
  • Others: This segment includes academic and research institutions.

By Region

  • Americas: The largest regional market, increasing government initiatives to promote research in the pharmaceutical and biotech sector will boost the market growth in this region. Firms in the US conduct over half the world's R&D in pharmaceuticals, which is about $75 billion and hold intellectual property rights on most new medicines.
  • Europe: Technological advancements in personalized medicine and proteomic field is leading to a rise in the adoption of cell lysis & disruption techniques.
  • Asia-Pacific: The fastest-growing regional market, Asia-Pacific is seeing a surge in the clinical trials and contract research and manufacturing activities owing to the growth in the bio-services sector is expected to boost the market growth.
  • Middle East & Africa: The smallest market due to limited healthcare infrastructure in this region.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/cell-lysis-disruption-market-8358 

Posted by at No comments:

Liver Cirrhosis Treatment Market Dynamics, Segments and Supply Demand 2020-2027

 Market Highlights

According to MRFR analysis, the global liver cirrhosis treatment market dynamics expected to register a CAGR of ~5.2% during the forecast period of 2019 to 2025 and was valued at USD 956.89 million in 2018.

Liver cirrhosis is basically the late-stage scarring of the liver caused due to various types of liver diseases and disorders such as alcoholism and hepatitis, among others. No symptoms are observed until the liver is extensively damaged. Complications of liver cirrhosis include portal hypertension, leg & abdomen swelling, splenomegaly, bleeding, infections, malnutrition, hepatic encephalopathy, jaundice, bone diseases, risk of liver cancer, and multi-organ failure.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/8367

The growth of the global liver cirrhosis treatment market is driven by various factors such as an increasing global geriatric population, rising prevalence of liver cirrhosis, rapidly changing lifestyle, growing awareness programs regarding liver diseases, rising R&D investment for the development of innovative drugs for liver diseases, and increasing demand for better treatment methods for curing liver cirrhosis. However, stringent government regulations, high investment required for drug research & development, and side-effects of medications prescribed for liver cirrhosis are the factors that are expected to limit the growth of the global liver cirrhosis treatment market.

The global liver cirrhosis treatment market is currently dominated by several market players. The key players are involved in product launches and strategic collaborations to strengthen their market positions.

Regional Analysis

The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is expected to be the largest market owing to the increasing prevalence of liver cirrhosis and high geriatric population. The liver cirrhosis treatment market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European liver cirrhosis treatment market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The liver cirrhosis treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Due to the increasing patient pool of liver cirrhosis and raising awareness about the disease, the market in Asia-Pacific is expected to be the fastest-growing. The liver cirrhosis treatment market in the Middle East & Africa has been divided into the Middle East and Africa.

Segmentation

The global liver cirrhosis treatment market has been segmented based on treatment, and end user.

The global liver cirrhosis treatment market has been segmented, on the basis of treatment, into antibiotics, immunosuppressants, and others. The antibiotics segment is expected to hold the majority share of the market as antibiotics are the most preferred type of prescribed drugs for liver cirrhosis patients due to high risk of infections. The immunosuppressants segment is expected to grow at the fastest CAGR, due to an increasing number of liver transplants. Till October 2017, 147,842 liver transplants have been performed in the Americas. Immunosuppressants are a type of drugs that are prescribed to patients who have undergone liver transplant so that the risk of organ rejection is decreased. Other treatment options include drugs to reduce ammonia levels, antihypertensive drugs, and medications to reduce blood pressure, among others.

The market on the basis of end user has been segmented into hospitals and clinics, research and academic institutes, and others. The hospitals and clinics segment is expected to hold the largest share of the market as they are primary centers of treatment for the patient. Research and academic institutes carry out research activities for the development of new treatment options for liver cirrhosis. Other end users include home care settings and specific centers for the treatment of elderly people.

Key Players

Some of the key players in the global liver cirrhosis treatment market are Pfizer, Inc. (US), Merck & Co., Inc. (Germany), Novartis AG (Switzerland), F. Hoffmann-La Roche Ltd (Switzerland), Takeda Pharmaceutical Company Limited (Japan), Gilead Sciences, Inc. (US), AstraZeneca (UK), Bayer AG (Germany), Sanofi (France), Shionogi Inc. (Japan), and Promethera (Belgium).

Posted by at No comments:

Forensic Swab Market 2020 Analysis, Industry Size, Share Leaders, Current Status by Major vendors and Trends by Forecast to 2027

 The Global Forensic Swab Market is expected to register 5.8% CAGR and is anticipated to reach USD 49.09 Million by 2023. Forensic swabs are extensively used by forensic scientists and crime scene investigators for collecting a wide range of evidence-samples such as blood, saliva, and DNA. These samples are analyzed in the laboratory for desired results. Gathering biological samples for successive DNA analysis is one of the major applications for forensic swabs. Rising criminal activities, increasing adoption of DNA forensics, growing forensic biotechnology sector, and favorable government support are some of the major factors driving the market growth during the forecast period. However, factors such as the high price of DNA free forensic swabs and irregular supply of new products in the market are projected to restrain the market growth. However, the growing rate of chronic and infectious diseases, increased research and development investment (R&D), and technological advancements are expected to boost the market growth.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/6929

Key Players

The prominent global forensic swab market manufacturers are Becton, Dickinson and Company Thermo Fisher Scientific Inc., Merck KGaA, Copan Italia S.p.A., MWE, SARSTEDT AG & Co. KG, Luna, Puritan Medical Products, Sirchie, and MEDTECH Forensics.

Market Dynamics

The past few years, there has been an increase in criminal activities and reported crimes has increased. According to crime statistics published by the Federal Bureau of Investigation, approximately 17,250 murders were estimated to be reported within the US in 2016. The government support for forensics-related activities is one of the major factors driving the global forensic swab market. The judicial framework of various countries has realized the importance of forensics. Currently, forensics is being utilized as toxicology forensics, DNA forensics, and others for investigating criminal offenses. According to a report on forensic science published by the National Criminal Justice Reference Service, the National Institute of Justice received a funding of USD 125 million through the Department of Justice Appropriations Act in 2017 for boosting DNA and other related forensic programs and activities and sexual assault forensic exams.

Segmentation

The global forensic swab market has been segmented into type, type of swab shaft, and end user.

Based on type, the global market has been segmented into foam, flocked, and cotton.

Based on type of swab shaft, the global market has been segmented into wood-stick shaft, polystyrene shaft.

Based on end user, the global market has been divided into forensic science laboratories and hospitals.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/forensic-swab-market-6929

About US:

 

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Posted by at No comments:

Viral Vector Manufacturing Market Top Companies, Business Insights, Growth, Global Market Share, Global Market Size, Trends, Sales, Revenue, Forecast and Detailed Analysis 2027

 Global Proteomics Market size is expected to grow significantly over the forecast period. It is anticipated that the market held a valuation of USD 23.2 Billion in 2017 and is projected to grow at a CAGR of 14.1% over the forecast period. Proteomes are a set of proteins which are produced in a system, organism, or any biological entity. Study of proteomes is known as proteomics. It is used in various applications, like investigation of protein expression, transcriptional & post transcriptional studies, metabolic pathways, protein interaction in diseases, etc.

The factors such as increasing research & development activities in the healthcare industry, rising demand for personalized medicines, rising number of approvals of personalized medicines and increasing activities of drug discovery are expected to propel the growth of the market. According to Foley & Lardner LLP, Food and Drug Administration (FDA) approved 16 new personalized medicine therapies in 2017. However, the high cost of devices and lack of skilled researchers can hamper the market growth over the forecast period.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6930 

Segmentation:

The Global Proteomics Market has been segmented into equipment, service and applicationThe market, on the basis of equipment, has been segmented into chromatography, mass spectroscopy, protein microarray, x-ray crystallography, protein fractionation and others.The market, by services, has been segmented into laboratory services and data analysis & services. The laboratory services segment accounted for the largest market share owing to its benefits in effective diagnosis and research for drug discovery. Data analysis and services is expected to register the highest CAGR owing to increasing demand for data analytics.The market, by application, has been segmented into drug discovery, clinical diagnosis and others.

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Proteomics Market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada. The European Proteomics Market has been segmented into Western Europe and Eastern Europe. Western Europe has been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.  The Proteomics Market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The Proteomics market in the Middle East & Africa has been segmented into the Middle East and Africa.

Key players:

GENERAL ELECTRIC COMPANY, Bio-Rad Laboratories, Inc., Danaher, Siemens Ltd., Thermo Fisher Scientific Inc. Inc., Agilent Technologies, Inc., Genzyme Corporation, Biognosys AG, Bruker, Luminex Corporation, Merck KGaA, PerkinElmer Inc., WATERS, Caprion Biosciences Inc. and others are some of the key players in the Global Proteomics Market.

Regional Market Summary

Geographically, the Americas is anticipated to dominate the global proteomics market owing to rising funding from government, rising awareness regarding applications of proteomics, cost effectiveness and increasing demand for personalized medicines. According to a report published in a journal named Leukemia Research in November 2017, personalized medicines improve life of cancer patients by 7 months at USD 32,000.

Europe is expected to hold the second largest position in the Global Proteomics Market. The market growth in this region is attributed to rising cancer research activities and government support. The proteomics market in Asia-Pacific region consists of countries namely China, Japan, Republic of Korea, India, Australia and the Rest of the Asia-Pacific. The Asia-Pacific region is expected to be fastest growing region owing to the increasing demand for personalized medicine due to rising prevalence of cancer and other such diseases and presence of large number of manufacturers of personalized medicines in the region. According to a report published by the National Institute of Cancer Prevention and Research (NICPR), around 2.25 million people in India are living with cancer in 2018.

The Middle East & Africa are expected to hold the least share of the market. The market growth in this region is expected to be driven by a developing healthcare infrastructure.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/proteomics-market-6930 

About US:

 

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Posted by at No comments:

Viral Vector Manufacturing Market 2020 Analysis, Industry Size, Share Leaders, Current Status by Major vendors and Trends by Forecast to 2027

 Global viral vector manufacturing market is expected to grow significantly over the forecast period. It is projected that the upcoming global viral vector manufacturing market trends  expected to register a CAGR Approx. 22.65% with an expected market value of USD 319 million during the forecast period of 2018–2023. Gene therapy is one of the preferred treatment options for most chronic diseases, involving insertion of a functional copy of a gene into a defective cell. Viral vector methods are used in effective transfer of therapeutic gene into the target cells. Viral vectors used in gene therapy include retroviral vectors, adenoviral vectors and adeno-associated viral vectors.

Numerous factors such as rise in number of clinical trials, increase in the number of gene therapy candidates, and growing necessity for an effective mode of disease treatment are expected to drive the growth of the market. Also, the characteristics of viral vectors such as ability to express therapeutic genes efficiently, and non-pathogenic nature fuels the growth of the market. Moreover, several companies involved in the development of viral agent-based products often seek support in terms of strategic collaborations and acquisitions with contract service providers to deliver a clinical grade product. This is mainly because of the limited availability and complexity of platform and technologies used for vector designing, production, packaging, and release testing. For example, in December 2017, Merck announced a commercial supply agreement to manufacture viral vectors for Bluebird Bio, Inc. for its use in potentially transformative gene therapies. This move will accentuate the life science business of Merck as a leading contract manufacturing organization and commercial provider of viral vectors for gene therapy.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6890 

However, high cost of gene therapies and possible mutagenesis may hamper the market growth during the assessment period.

Segmentation:

The global viral vector manufacturing market has been segmented into type, disease, application, and end-user.

The market, on the basis of type, has been segmented retroviral vectors, adenoviral vectors, adeno-associated viral vectors, and other viral vectors.

The segment, by retroviral vectors is anticipated to be the largest segment. Retro viruses contain an enzyme reverse transcriptase which allows the integration into the host genome. This has increased the usage of retroviral vectors in various treatment options, whereas the adenoviral vectors segment is estimated to be the fastest growing segment owing to their increased use in the in-vivo and in-vitro experiments.

The market, by retroviral vectors, has been further segmented into lentiviral vectors and gamma-retroviral vectors.

The market, by disease, has been segmented into cancer, genetic disorders, infectious diseases, and others.

The market, by application, has been segmented into gene therapy and vaccinology.

The market, by end-user, has been segmented into pharmaceutical and biotechnology companies, research institutes, and others.

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The viral vector manufacturing market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European viral vector manufacturing market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 

The viral vector manufacturing market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The viral vector manufacturing market in the Middle East & Africa has been segmented into the Middle East and Africa.

Key players:

FUJIFILM Diosynth Biotechnologies U.S.A., Inc., Sanofi, Lonza, Merck KGaA, GENERAL ELECTRIC COMPANY, Oxford BioMedica, Spark Therapeutics, Inc., uniQure N.V., FinVector Vision Therapies, Brammer Bio, Cell and Gene Therapy Catapult, Cobra Biologics, REGENXBIO Inc., and Kaneka Eurogentec S.A. are some of the key players in the global viral vector manufacturing market.

Regional Market Summary

Geographically, the Americas is anticipated to dominate the global viral vector manufacturing market owing to a well-developed healthcare sector and rising prevalence of autoimmune and chronic diseases. According to a study published by Partnership to Fight Chronic Disease (PFCD) in 2016, 191 million people in America had at least 1 chronic disease, whereas 75 million had 2 or more chronic diseases in the year 2015.

Europe is expected to hold the second largest position in the global viral vector manufacturing market. The market growth in this region is attributed to the availability of funds for research and increasing healthcare expenditure. According to the European Commission, in 2016 the total expenditure of the governments of the European Union on health amounted to 7.1% of GDP. Also, according to National Institute of Health Funding (NIHR) in the year 2016, a funding of Euro 928 million was announced for new NIHR Biomedical Research Centres (BRC) and NIHR Clinical Research Facilities (CRF) for 5 years starting from April 2017.

Asia-Pacific is anticipated to be the fastest growing region in the market due to the presence of a huge patient population and continuously developing economies.

On the other hand, the Middle East and Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle East region due to the growing government initiatives for the healthcare sector.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/viral-vector-manufacturing-market-6890 

About US:

 

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Posted by at No comments:
Subscribe to: Comments (Atom)